Background
Methods
Patients and specimens
Tissue microarrays
Immunohistochemistry
Fluorescence in situ hybridization
Follow-up information
Statistical analysis
Results
Characterization of ESCC patients
EGFR IHC analysis
Pairs | Levels | Number |
P
| Kappa |
---|---|---|---|---|
System 1 vs. System 6 | (L/M/H) vs. (L/M/H) | (49/39/8) vs. (14/33/49) | 0.001 | 0.037 |
System 2 vs. System 3 | (L/H) vs. (L/H) | (42/54) vs. (48/48) | 0.031 | 0.875 |
System 2 vs. System 4 | (L/H) vs. (L/H) | (42/54) vs. (88/8) | 0.001 | 0.132 |
System 2 vs. System 5 | (L/H) vs. (L/H) | (42/54) vs. (12/84) | 0.001 | 0.31 |
System 3 vs. System 4 | (L/H) vs. (L/H) | (48/48) vs. (88/8) | 0.001 | 0.167 |
System 3 vs. System 5 | (L/H) vs. (L/H) | (48/48) vs. (12/84) | 0.001 | 0.25 |
System 4 vs. System 5 | (L/H) vs. (L/H) | (88/8) vs. (12/84) | 0.001 | 0.026 |
EGFR gene copy variation
Correlation between EGFR protein expression and gene variation
EGFR-FISH result | ||||||
---|---|---|---|---|---|---|
EGFR-IHC | FISH positive | Amplification | ||||
No | Yes |
P
| No | Yes |
P
| |
System 1 | 0.034 | 0.001 | ||||
L | 39 | 10 | 9 | 0 | ||
M | 25 | 14 | 37 | 2 | ||
H | 3 | 5 | 3 | 5 | ||
System 2 | 0.036 | 0.015 | ||||
L | 34 | 8 | 42 | 0 | ||
H | 31 | 21 | 47 | 7 | ||
System 3 | 0.120 | 0.006 | ||||
L | 37 | 11 | 48 | 0 | ||
H | 30 | 18 | 41 | 7 | ||
System 4 | 0.038 | 0.001 | ||||
L | 64 | 24 | 86 | 2 | ||
H | 3 | 5 | 3 | 5 | ||
System 5 | 0.674 | 0.299 | ||||
L | 9 | 3 | 12 | 0 | ||
H | 58 | 26 | 77 | 7 | ||
System 6 | 0.175 | 0.027 | ||||
L | 11 | 3 | 14 | 0 | ||
M | 26 | 7 | 33 | 0 | ||
H | 30 | 19 | 42 | 7 | ||
Total | 67 | 29 | 89 | 7 |
Prognostic implication of EGFR protein expression levels and gene variation
EGFR-IHC result | EGFR-FISH result | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
System 1 | System 4 | FISH Positive | Amplification | |||||||||||
N | L | M | H |
P
| L | H |
P
| No | Yes |
P
| No | Yes |
P
| |
Gender | ||||||||||||||
Male | 80 | 42 | 32 | 6 | 0.724 | 74 | 6 | 0.509 | 52 | 28 | 0.022 | 74 | 6 | 0.861 |
Female | 16 | 7 | 7 | 2 | 14 | 2 | 15 | 1 | 15 | 1 | ||||
Age | ||||||||||||||
<60 | 34 | 24 | 8 | 2 | 0.017 | 22 | 12 | 0.422 | 22 | 12 | 0.422 | 32 | 2 | 0.694 |
>60 | 62 | 25 | 31 | 6 | 45 | 17 | 45 | 17 | 57 | 5 | ||||
Tumor site | ||||||||||||||
Upper | 1 | 0 | 1 | 0 | 0.181 | 1 | 0 | 0.607 | 1 | 0 | 0.313 | 1 | 0 | 0.413 |
Middle | 33 | 12 | 17 | 4 | 29 | 4 | 20 | 13 | 29 | 4 | ||||
Lower | 62 | 37 | 21 | 4 | 58 | 4 | 46 | 16 | 59 | 3 | ||||
T-stage | ||||||||||||||
T1 | 5 | 2 | 3 | 0 | 0.889 | 5 | 0 | 0.499 | 3 | 2 | 0.552 | 5 | 0 | 0.602 |
T2 | 24 | 13 | 9 | 2 | 23 | 1 | 15 | 9 | 23 | 1 | ||||
T3 | 67 | 34 | 27 | 6 | 60 | 7 | 49 | 18 | 61 | 6 | ||||
Vaso invasion | ||||||||||||||
No | 77 | 34 | 35 | 8 | 0.020 | 69 | 8 | 0.142 | 54 | 23 | 0.884 | 70 | 7 | 0.172 |
Yes | 19 | 15 | 4 | 0 | 19 | 0 | 13 | 6 | 19 | 0 | ||||
Nerve invasion | ||||||||||||||
No | 62 | 34 | 24 | 4 | 0.497 | 59 | 3 | 0.094 | 44 | 18 | 0.735 | 59 | 3 | 0.212 |
Yes | 34 | 15 | 15 | 4 | 29 | 5 | 23 | 11 | 30 | 4 | ||||
LN metastases | ||||||||||||||
No | 52 | 29 | 22 | 1 | 0.046 | 51 | 1 | 0.013 | 39 | 13 | 0.227 | 51 | 1 | 0.028 |
Yes | 44 | 20 | 17 | 7 | 37 | 7 | 28 | 16 | 38 | 6 | ||||
Necrosis | ||||||||||||||
No | 38 | 21 | 16 | 1 | 0.258 | 36 | 2 | 0.378 | 27 | 11 | 0.828 | 37 | 1 | 0.155 |
Yes | 58 | 28 | 23 | 7 | 52 | 6 | 40 | 18 | 52 | 6 | ||||
Mitoses (/10HPF) | ||||||||||||||
≤20 | 29 | 12 | 15 | 2 | 0.645 | 27 | 2 | 0.307 | 18 | 11 | 0.06 | 27 | 2 | 0.768 |
20~50 | 37 | 20 | 13 | 4 | 32 | 5 | 31 | 6 | 35 | 2 | ||||
≥50 | 30 | 17 | 11 | 2 | 29 | 1 | 18 | 12 | 27 | 3 | ||||
Tumour differentiation | ||||||||||||||
G2 | 61 | 33 | 26 | 2 | 0.061 | 43 | 18 | 0.844 | 43 | 18 | 0.844 | 57 | 4 | 0.715 |
G3 | 35 | 16 | 13 | 6 | 24 | 11 | 24 | 11 | 32 | 3 |